Lupin’s Pithampur Unit Receives Two U.S. FDA Observations 
Capsules move along a production line at Lupin Ltd.’s plant in Salcette, Goa. (Photographer: Dhiraj Singh/Bloomberg)

Lupin’s Pithampur Unit Receives Two U.S. FDA Observations 

Bookmark

Drug firm Lupin Ltd. on Wednesday said the U.S. health regulator has issued two observations after inspection of the company's Madhya Pradesh facility.

The inspection of the company's Pithampur Unit-I facility by the United States Food and Drug Administration has been completed, Lupin said in a filing to BSE.

The inspection carried out between Feb. 3 and Feb. 11, 2020, closed with two 483 observations, it added.

An FDA Form 483 is issued to a firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts. It notifies the company's management of objectionable conditions at the facility.

We uphold the highest standards of quality and compliance across our manufacturing operations and are committed to consistently produce and distribute products of the highest quality.
Nilesh Gupta, Managing Director, Lupin

Shares of Lupin were trading at Rs 703.20 per scrip on BSE, down 0.26 percent from the previous close.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.